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Chorea-acanthocytosis (ChAc) is a rare autosomal recessive inherited syndrome
characterized by hyperkinetic movements, seizures, cognitive impairment,
neuropsychiatric symptoms, elevated serum biochemical indicators and acanthocytes
detection in peripheral blood smear. Vacuolar protein sorting 13A (VPS13A) gene
mutations have been proven to be genetically responsible for the pathogenesis of
ChAc. Herein, based on the typical clinical symptoms and neuroimaging features, we
present two suspected ChAc cases which are further genetically confirmed by four novel
VPS13A gene mutations. Nevertheless, the sharp contrast between the population
base and published ChAc reports implies that ChAc is considerably underdiagnosed in
China. Therefore, we conclude several suggestive features and propose a diagnostic
path of ChAc from a clinical, genetic and neuroimaging perspective, aiming to facilitate
the diagnosis and management of ChAc in China.
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INTRODUCTION
Neuroacanthocytosis (NA) syndromes encompass a group of rare diseases characterized by
the presence of “thorny” red blood cells (acanthocytes) in peripheral blood smear and
neurodegeneration of the basal ganglia, along with hyperkinetic movement, seizures, cognitive
impairment, and neuropsychiatric manifestations (Walker et al., 2011). Chorea-acanthocytosis
(ChAc, OMIM 200150) occupies the main entity of this disease group which also includes McLeod
syndrome (MLS), Huntington’s disease-like 2 (HDL2) and, more rarely, pantothenate kinase-
associated neurodegeneration (PKAN) (Walker et al., 2011). From a perspective of genotype,
ChAc mainly follows an autosomal recessive (AR) inheritance pattern (Danek et al., 2012),
and the causative gene is vacuolar protein sorting 13A (VPS13A), a large gene consisting of
73 exons located in chromosome 9q21 (Walker et al., 2012). Up to now, the VPS13A gene
mutation types reported ever include missense, nonsense, frameshift, duplication, deletion and
splice site mutations (Velayos-Baeza et al., 2004). Chorein, the VPS13A gene expression product,
is ubiquitously detected in a wide variety of human tissues (Dobson-Stone et al., 2004), which has
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been proven to be markedly reduced or absent in ChAc
patients with the mutations described above (Dobson-Stone
et al., 2004; Velayos-Baeza et al., 2004). While viewing from
phenotypic aspects, ChAc can manifest as chorea, dystonia,
cognitive impairment, seizures, psychosis, and even Parkinsonian
features (Ueno et al., 2001), thus bearing immense resemblance
to Huntington’s disease, dystonia, epilepsy, Parkinsonism, etc.
Hence, the multifarious VPS13A mutation patterns, intricate
symptom complex and overlapped clinical features enable
diagnosis and differential diagnosis of ChAc an enormous
challenge.
Herein, we report two clinical cases diagnosed with
ChAc, varying from VPS13A mutation patterns, presenting
manifestations, symptom spectrum to laboratory biomedical
indicators. After a retrospective review of the ChAc case ever
reported, we regrettably find that few cases are from China.
Moreover, in light of the sharp contrast between population
base and reported cases in China and the global prevalence
of ChAc, it can be concluded that the morbidity of ChAc has
been underdiagnosed in China (Liu et al., 2014). Based on the
ChAc literatures ever published and these two cases, we conclude
several suggestive features and propose a diagnostic path of
ChAc, aiming to facilitate the future diagnosis and management
of ChAc in China.
CASE PRESENTATION
Two confirmed ChAc patients, once admitted into Department of
Neurology, Union Hospital, Tongji Medical College, Huazhong
University of Science and Technology (TJMC, HUST), were
interviewed and surveyed retrospectively, and their medical
records were thoroughly reviewed. Besides, relevant clinical and
imaging data during the periodic outpatient follow-ups were
consulted as well.
Ethics Statement
This study was carried out in accordance with the guidelines of
institutional ethics committee of Union Hospital, TJMC, HUST.
All subjects gave written informed consent on the basis of the
Declaration of Helsinki.
Case 1
A 37-year-old man, a warehouse keeper, presented with perioral
chorea, dysphagia, dysarthria, vocalization, and involuntary
upper limb movements for 5 months. His symptoms had
been gradually progressing, aggravated recently by involuntary
self-mutilation behaviors: tongue and lip biting. The past
history revealed that he was diagnosed with generalized tonic–
clonic seizure (GTCS) at age 30, but maintaining continuous
remission with regular sodium valproate administration. On
neurological examination, the patient showed perioral chorea,
reduced muscle tone and tendon reflex and sporadic mouth
ulcers, especially accompany frequent suck-mimicking activity.
Upon admission screening stage, the laboratory biomedical
tests revealed a considerable elevation in serum creatine kinase
(CK), l-lactate dehydrogenase (LDH) and alpha hydroxybutyrate
dehydrogenase (HBDH), especially for CK reaching up to
seven-fold (see Table 1). The subsequent brain magnetic
resonance imaging (MRI) scanning indicated moderate anterior
horn dilation of lateral ventricles and mild caudate nucleus
head atrophy (see Figure 1A-left column). Based on the
clinical features, neurological examination findings and auxiliary
test results available, we proposed the probable diagnosis of
ChAc. Then four repeated and independent blood smears were
performed, revealing that acanthocytes ratio averaged to 18% of
the complete blood count (CBC) (see Figure 1B-left column). To
further confirm the diagnosis, the VPS13A gene was sequenced
subsequently. As expected, a heterozygous frameshift mutation in
exon 52 (c.7276_7280delCAATA) and a heterozygous nonsense
mutation in exon 60 (c.8278C>T) had been determined, which
probably gave rise to the premature translation termination
and even nonsense-mediated decay (NMD) pathway induced
VPS13A-mRNA degradation (Kervestin and Jacobson, 2012)
(see Figure 2A and Table 1). Besides, subsequent Sanger
sequencing also confirmed the heterozygous frameshift and
nonsense mutations (see Figure 2A). Moreover, the HD-IT15
gene (CAG)n analysis had also been performed to exclude
the possible comrbidity of HD, but revealing no pathogenic
mutations. In conclusion, the patient was ultimately diagnosed
with ChAc and prescribed haloperidol, tiapride to control his
perioral chorea (Diederich et al., 1990). Besides, given that
vitamin E was once reported to relieve ChAc symptoms by means
of improving red blood cell membrane fluidity (Hardie, 1989),
it was tentatively administrated as well. As a result, his perioral
chorea and self-mutilation behaviors were alleviated 3 days later
and he was discharged after a week of clinical observation.
Case 2
A 45-year-old housewife gradually developed involuntary
bruxism (teeth grinding), dysphagia, dysarthria, vocalization,
and frequent self-mutilation behaviors (tongue and lip biting)
after a recovery from a severe mouth ulcer 1 month ago. Her
orofacial chorea was characterized by clumsy, non-coordinated
mandibular movement and occasional grimacing activities.
A further family history inquiry revealed no similar symptom
presenters. On neurological examination, she showed frequent
teeth clenching, reduced limb muscle tone and tendon reflex
and multiple lip ulcers. To prevent the risk of self-mutilation,
she had to continuously hold a roll of cloth in her mouth.
The serum CK, LDH, and HBDH levels are all within normal
ranges (see Table 1). On the basis of clinical features and
serum biomchemical indicators, the patient was temporarily
diagnosed with oromandibular dystonia. But a routine blood
smear test accidentally detected acanthocytes, which thereby led
us to the assumptive diagnosis of ChAc. Subsequently, three
repeated and independent peripheral blood smears conformably
detected acanthocytes, with acanthocytes ratio averaged to 17%
of CBC (see Figure 1B-right column). Besides, brain MRI
scanning demonstrated mild atrophy in the caudate head and
putamen bilaterally, accompanying moderate anterior horn
dilation of lateral ventricles (see Figure 1A-right column).
Moreover, the VPS13A gene sequencing further confirmed
the diagnosis, revealing a heterozygous nonsense mutation
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TABLE 1 | A summary of the diagnostic evidences identified in the affected ChAc patients.
Items Patient 1 Patient 2
Gender/age at onset Male/37 Female/45
Occupation Warehouse keeper Housewife
Family history – –
Primary symptoms Perioral chorea, frequent sucking–mimicking Bruxism, involuntary tongue and lip biting
Incipient symptom GTCS Bruxism
Dystonia distribution Oromandibular region, upper limbs Oromandibular region
Dysarthria +++ +
Tongue and lip biting + +++
Parkinsonian features – –
Tendon reflex Areflexia of four limbs Hyporeflexia of lower extremities
Seizure type GTCS –
Cognitive impairment ++ +
Psychiatric symptoms Apathy, depression Apathy, anxiety
EMG Axonal neuropathy Axonal neuropathy
CK (38-170U/L) 1122 137
LDH (109-245U/L) 314 175
HBDH (72-182U/L) 247 159
ALT (5-40U/L) 34 14
AST (8-40U/L) 47 15
Acanthocyte ratio of CBC 18% 17%
MRI Moderate caudate nucleus head atrophy and paracele anterior horn dilation Mild caudate nucleus head and putamen atrophy
HD-IT15 gene (CAG)n analysis No pathogenic mutation No pathogenic mutation
VPS13A sequence changes c.7276_7280delCAATA c.8278C>T c.8282C>G c.9276-1G>A
Chorein alterations p.Gln2426GlnfsX7 p.Gln2760Ter p.Ser2761Ter Splicing mutation
Mutation types Frameshift mutation (exon52) Nonsense mutation (exon60) Nonsense mutation (exon60) Splicing mutation (intron69)
(+++, severe;++, moderate;+, mild; –, none); GTCS, generalized tonic–clonic seizure; CK, creatine kinase; LDH, l-lactate dehydrogenase; HBDH, alpha hydroxybutyrate
dehydrogenase; ALT, alanine transaminase/glutamic-pyruvic transaminase; AST, aspartate transaminase/glutamic–oxaloacetic transaminase; HD, Huntington’s disease;
EMG, electromyography; CBC, complete blood count; Gln, glutamine; Ser, serine; Ter, termination codon.
(c.8282C>G→p.Ser2761Ter) in exon 60 and a heterozygous
splicing mutation (c.9276-1G>A) in intron 69 (see Figure 2B
and Table 1). Nevertheless, the VPS13A gene sequencing in
this patient’s daughter, a healthy girl with no sign of ChAc,
identified a heterozygous splicing mutation similar her mother’s
in intron 69 (c.9276-1G>A) (see Figure 2B). As a matter of
fact, the inheritance pattern of ChAc was reported to vary from
AR inheritance (predominant pattern), autosomal dominant
inheritance to X linked recessive inheritance pattern (Ueno
et al., 2001; Dobson-Stone et al., 2002), accompanying different
levels of penetrance in different sufferers or families (Saiki
et al., 2003; Walker et al., 2007). Therefore, when postulating
that ChAc is inherited in an AR inheritance and complete
penetrance pattern in this family, the healthy girl is probably
a carrier of pathogenic VPS13A gene. In conclusion, according
to the clinical symptoms, neuroimaging features and, especially,
genetic findings, the patient was finally diagnosed with ChAc.
Then the patient received botulinum toxin (BTX) injection
to relieve her torturous bruxism and self-mutilation behavior,
eventually achieving prominent remission. In the outpatient
follow-up 4 months later, she was also routinely prescribed
haloperidol and vitamin E to control chorea (Diederich et al.,
1990) and improve the red blood cell membrane fluidity (Hardie,
1989) and it subsequently presented satisfactory therapeutic
effects.
DISCUSSION AND LITERATURE REVIEW
In this study, we present two ChAc cases on the basis of clinical
symptoms, neuroimaging features, and VPS13A genetic findings.
While a retrospective study of the ChAc cases ever reported
revealed that there probably exists a considerable underdiagnosis
of ChAc in China (Liu et al., 2014). Given this stern status quo of
ChAc management, we propose several suggestive features and
a diagnostic path of ChAc (see Table 2), which can be used to
facilitate the diagnosis and management of ChAc in China.
Clinical Features
Chorea-acanthocytosis mostly present in early adulthood,
between age 20 and 40 and rarely before age 20 or after 50 (Walker
et al., 2007), generally with hyperkinetic involuntary movements
as typical symptoms (Walker, 2015). As a matter of fact, perioral
chorea, bruxism and self-mutilation behaviors, demonstrated
by the two patients, are all concrete manifestations of the
hyperkinetic movements (see Tables 1, 2). In particular, several
previous reports have already indicated that self-mutilation,
especially tongue and lip biting, were critically suggestive of
ChAc (Walker et al., 2006, 2007; Gooneratne et al., 2014)
(see Tables 1, 2). What is interesting is that the self-mutilation
behaviors can be considerably alleviated by holding a roll of cloth
in mouth just as performed by patient 2. This phenomena can be
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FIGURE 1 | Neuroimaging and cytological features identified in ChAc patients. (A) Axial and coronal view of the basal ganglion plane in patient 1 (left) and
patient 2 (right) demonstrated similar MR imaging features: caudate nucleus head atrophy and anterior horn dilation of lateral ventricles (marked by arrows).
(B) Acanthocytes (marked by arrows, Giemsa staining) were detected in peripheral blood smear under light microscope examination. The average acanthocytes ratio
in patient 1 and 2 were 18% (left) and 17% (right), respectively. (C) Schematic diagram of striatal atrophy pattern in ChAc patient. The caudate nucleus head atrophy
demonstrated a dorsal to ventral pattern (marked by yellow), while the putamen presented a caudate to rostral mode (marked by black).
interpreted as direct mechanic protections or a certain form of
sensory trick (Bader et al., 2010; Walker, 2015).
Seizures and neuropathy are also relatively common features
of ChAc (see Tables 1, 2). It has been speculated that about
42% of patients have at least one seizure attack during their
clinical courses (Rampoldi et al., 2002). In general, seizure are
mostly antiepileptic drugs (AEDs) sensitive GTCS in ChAc,
just as proven in patient 1, but simple and complex partial
seizures have been described as well (Al-Asmi et al., 2005; Walker
et al., 2007). For example, a recent study had identified a rare
c.2343del VPS13A gene mutation in three Israeli families, in
which most affected individuals presented seizures as the first
and dominant symptom (Benninger et al., 2016). Moreover,
seizures of this type could be of temporal lobe origin and were
AEDs resistant in five out of nine patients (Benninger et al.,
2016). Peripheral sensorimotor neuropathy with the absence
of deep tendon reflexes is common in NA, and it can be no
easy to differentiate from motor neuron disease (Neutel et al.,
2012). Nevertheless, the neuroelectrophysiological abnormities
predominantly prove to be axonal neuropathy in ChAc (Walker
et al., 2007) (see Tables 1, 2), which is quite different from that of
motor neuron disease.
Dysphagia and dysarthria are also common symptoms in
ChAc (see Tables 1, 2), resulting from progressive swallowing
and vocal musculature dysfunction. While in the initial stages
swallowing and speech impairment are likely due to orolingual
dystonia, patients often become mute as the disease proceeds
into terminal stages, thus implying an involvement of central
nervous system dysfunction (Walker, 2015). Additionally,
Parkinsonism are also involved in the symptom spectrum as a
presenting or accompanying symptom, especially in later stage
with the encroachment of the direct and indirect pathways
(Bostantjopoulou et al., 2000).
Patients diagnosed with ChAc often present neuropsychiatric
symptoms prior to the development of movement disorders
(Walker, 2015). In general, psychiatric symptoms include
apathy, anxiety, depression, obsessive-compulsive disorders, and
agitation, which are also precisely confirmed by the affected
patients in this study (see Tables 1, 2). Cognitive impairments
range from mild cognitive impairment to dementia, with
deficits mainly manifesting as memory decline and executive
dysfunction.
Serum biochemistry reveals that CK, LDH, and HBDH are
elevated in the vast majority (about 85%) of ChAc patients and
it may precede the appearance of neurologic symptom as a
sign of subclinical myopathy (Lossos et al., 2005; Walker, 2015).
However, the serum biochemical alteration are not mandatory
for the diagnosis of ChAc, just as proven by patient 2 whose
CK, LDH, and HBDH values are all within normal ranges (see
Table 1). Nevertheless, CK elevation is not associated with HDL2,
PKAN, and HD, thus enabling serum CK a relatively more
specific indicator for ChAc (see Table 2) especially in China when
compared with other biochemical indicators (Liu et al., 2014).
Acanthocyte detection in peripheral blood smear is a specific
indicator for the diagnosis of ChAc (see Figure 1B and
Table 1). However, the detection efficiency of acanthocytes is
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FIGURE 2 | Sequencing analysis of the VPS13A gene in ChAc patients and family member. (A) High-throughput sequencing of VPS13A gene (NM_033305)
in patient 1 reveals a 5 bp heterozygous deletion (c.7276_7280delCAATA) in exon 52 (A1) and a substitution of T for C (c.8278C>T) in exon 60 (A2). Moreover, the
frameshift mutation and nonsense mutation have been confirmed by the Sanger sequencing method precisely. (B) Chip capture high throughput sequencing of
VPS13A gene (NM_033305) in patient 2 shows a substitution of G for C (c.8282C>G) in exon 60 (B1) and an aberrant splicing pattern (c.9276-1G>A) in intron 69
(B2). While, in contrast, her daughter only shows a heterozygous splicing mutation similar to her mother’s in intron 69 (c.9276-1G>A) (B2), but not the nonsense one
in exon 60 (B1).
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TABLE 2 | Proposed diagnostic path of ChAc.
Evidence Categories Details
I. Clinical clues (is mandatory) 1 Hyperkinetic movements (e.g., perioral or oromandibular dystonia, feeding dystonia; grimacing activities, limb choreic
movements) most common cues
2 Self-mutilation behaviors (especially tongue and lip biting; sporadic mouth ulcers) most suggestive cues
3 Bruxism (teeth grinding behaviors)
4 Dysarthria, dysphasia, articulation disorders
5 Seizures attack (GTCS, simple or complex partial seizures)
6 Parkinsonian symptoms (e.g., bradykinesia, rigidity)
7 Neuropsychiatric symptoms (e.g., apathy, anxiety, depression, agitation, cognitive impairment)
8 Diminished or absent tendon reflex (axonal neuropathy proved by EMG)
II. Neuroimaging traits 9 Caudatum (especially caudate nucleus head) and lenticula atrophy (determined by striatal volumetry and morphometry), anterior
horn dilation of lateral ventricles
III. Laboratory inspection 10 Serum chemistry indicators: CK, LDH, HBDH, ALT, and AST elevation CK elevation, comparatively more specific indicator
11 Acanthocyte detection (peripheral blood smear or scanning electron microscope inspection) most suggestive evidence
12 Chorein detection (reduced or absent chorein blot) most confirmatory evidence
IV. VPS13A gene sequencing 13 Pathogenic VPS13A mutation (e.g. missense, nonsense, frameshift, duplication, deletion, and splice site mutations) most
confirmatory evidence
The diagnosis of ChAc is proposed to be established on the basis of four categorical evidences: clinical clues, neuroimaging traits, laboratory inspection, and VPS13A
gene sequencing. According to different evidence combinations, the diagnosis of ChAc can be classified into three subcategories: possible ChAc, probable ChAc, and
definite ChAc.
(1) Possible ChAc: 1 2 + 9 or 10 are mandatory, optional items from 3 − 8 (excluding other organic diseases and dystonia);
(2) Probable ChAc: 1 11 are mandatory, optional items from 2 − 13 (excluding other organic diseases and dystonia);
(3) Definite ChAc: 1 + 12 or 13 are mandatory, optional items from 2 − 11 (excluding other organic diseases and dystonia)
Attention: Apart from the mandatory items, the more supportive evidences, the more definite of the establishment of each diagnostic subcategory.
largely dependent on several specific endogenous factors and
blood sample treatment methods, and their absence does not
absolutely exclude the diagnosis of ChAc (Bayreuther et al., 2010).
Scanning electron microscopy is the most reliable morphological
diagnostic method, but it is still not routinely popularized.
Therefore, chorein detection (Velayos-Baeza et al., 2004) or
VPS13A gene sequencing (Walker et al., 2012) can be proposed
to be alternatives in the scenario of acanthocyte detection failure.
Genetic Findings
ChAc, an AR inherited movement disorder, can be attributed to
VPS13A gene mutation on chromosome 9q21. The previously
reported VPS13A mutation patterns include missense,
nonsense, frameshift, duplication, deletion, and splice site
mutations (Dobson-Stone et al., 2004). In this study, the
VPS13A gene sequencing in patient 1 revealed a heterozygous
frameshift mutation in exon 52 (c.7276_7280delCAATA) and
a heterozygous nonsense mutation in exon 60 (c.8278C>T),
while in patient 2 and her daughter identified a heterozygous
nonsense mutation (c.8282C>G) in exon 60 and a heterozygous
splicing mutation (c.9276-1G>A) in intron 69 (see Figure 2
and Table 1). In general, the mutations described above may
probably give rise to premature translation termination, NMD
pathway induced VPS13A-mRNA degradation (Kervestin and
Jacobson, 2012), abnormal spliceosome formation and even
production of aberrant chorein, which can genetically contribute
to the occurrence of ChAc.
What is interesting is that a recent study revealed a rare
c.2343del mutation in three ChAc Israeli families in which
seizures present as the premier and prominent symptoms
(Benninger et al., 2016). Moreover, the seizures presented in
these families were, in large part, of temporal origin and partly
AEDs resistant (Benninger et al., 2016). A retrospective review
of ever published literatures indeed indicates the presence of
epilepsy at early stages of NA (Hardie et al., 1991; Schwartz
et al., 1992; Kazis et al., 1995; Aasly et al., 1999; Al-Asmi et al.,
2005), but scarcely in the case of ChAc. In comparison, orofacial
and oromandibular chorea are typical symptom in both affected
patients in our study, but the presenting symptom in patient
1 is GTCS while in patient 2 is bruxism (see Tables 1, 2).
Given the novel and disparate VPS13A gene mutations identified
in patient 1 and patient 2, it can be presumed that particular
incipient symptoms may be associated with some specific
VPS13A mutations, just as corroborated by the relevance of
c.2343del mutation to epilepsy in Israeli families (Benninger
et al., 2016). Nevertheless, restricted by the sample sizes in this
study, it is imperative to investigate the intriguing proposition of
genotype–phenotype correlation in larger ChAc groups in future
study.
Hence, in light of the miscellaneous incipient symptom at
early stages of ChAc, the VPS13A gene sequencing can be
regarded as a reliable diagnostic and research tool. As a matter of
fact, it is precisely the novel VPS13A gene mutations have finally
helped to confirm the suspected ChAc cases in this study.
Neuroimaging Traits
The ChAc patients, on postmortem, typically presented atrophy
of the caudate nucleus, putamen, and globus pallidum, in
some cases involving substantia nigra as well, but usually
sparing cerebral cortex, cerebellum, locus coeruleus, inferior
olives, and other brain regions (Hardie et al., 1991; Henkel
et al., 2006). From a neuropathological perspective, marked
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neuronal loss and astrocytic gliosis were frequently observed,
especially in the caudate nucleus (Ishida et al., 2009). Brain
MR scanning in established ChAc patients also mirrored
these findings, demonstrating similar macroscopic features,
with caudate nucleus head being the most vulnerable region
(Walterfang et al., 2008; Ishida et al., 2009) (see Figures 1A,C).
Given the significance of caudate nucleus in ChAc, several
neuroimaging studies on caudate nucleus volume and shape
alterations had been performed. By means of voxel-based
morphometry (VBM) approach, Henkel et al. (2006) reported
a focal and symmetrical atrophy in the caudate nucleus when
comparing six patients with 15 age-matched controls. Later,
Huppertz et al. (2008) further confirmed the conclusion with
normalized VBM which could distinguish ChAc solely on the
basis of caudate volumetry. These two studies had proven volume
reduction in caudate nucleus and established a neuroimaging
indicator (caudate volumetry) in the diagnosis of ChAc, but
not investigating the morphometric changes. Walterfang et al.
(2011) advanced the study with the help of non-parametric
spherical harmonic technique which confirmed marked caudate
shape alterations in ChAc. Nevertheless, the shape and volume
alterations did not manifest uniformly, but with a prominent
predilection to caudate nucleus head (Walterfang et al., 2011)
(see Figures 1A,C). More specifically, the caudate nucleus
atrophy revealed a dorsal to ventral gradient, while in putamen
demonstrated a caudal to rostral pattern (Walterfang et al., 2011)
(see Figure 1C). This particular pathological changes might be
associated with the neuropsychiatric or cognitive symptoms in
the early stage of ChAc, in light of the crucial role of caudate
nucleus in frontostriatal loops (Leh et al., 2007; Draganski et al.,
2008; Utter and Basso, 2008). In conclusion, based on the
neuroimaging features identified in ChAc, the striatal volumetry
and morphometry could be proposed as promising neuroimaging
diagnostic indicators in future clinical practice.
CONCLUSION
Here in this study, we present the clinical symptoms,
neuroimaging features and VPS13A gene sequencing results
of two patients, which all finally support the diagnosis of
ChAc. Besides, four novel VPS13A gene mutations have been
identified, which genetically corroborate the pathogenesis of
ChAc and expand the VPS13A gene mutation spectrum as
well. Nevertheless, it has been revealed that only a handful
of cases are from China in a retrospective review of the
published ChAc cases (Liu et al., 2014). Hence, in light of China’s
tremendous population base, rare ChAc case reports and the
overall prevalence worldwide, it can be presumed that there may
exist an underdiagnosis of ChAc in China (Liu et al., 2014).
Confronted with such frustrating status quo, we have
concluded several suggestive indicators and proposed a
diagnostic path of ChAc on the basis of ever published reports
and the present two cases, which falls into the range of clinical
clues, neuroimaging traits, laboratory inspections and genetic
findings, respectively: (1) clinical clues: oromandibular and
feeding dystonia, self-mutilation behaviors (tongue and lip
biting); (2) neuroimaging traits: paracele anterior horn dilation
and caudate nucleus head atrophy; (3) laboratory inspections:
serum CK elevation and acanthocytes detection; (4) genetic
findings: familial aggregation, positive family history, and
pathogenic VPS13A gene mutations discovery; (see Tables 1, 2).
In conclusion, we expect the reported cases and proposed
diagnostic path could facilitate the future diagnosis and
management of ChAc in China.
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